Coruvs | Ciforadenant | MORPHEUS phase 1b/2 | ESMO poster #1315P | Atezolizumab; SOC | NSCLC | ORR: 18.2% (n=11) |
(CPI-444) | Phase 1/1b: NCT02655822 | Fong et al | Atezolizumab | Advanced RCC | ORR: 3% (n=33) (mono) |
| Cancer Disc. 2020 | ORR: 11% (n=35) (combo) |
| ASCO 2020 poster #94 | Tumor regression observed in 6/10 CD68 +pts (n = 3 mono; n=3 combo) |
| AACR 2017 Abstract CT119 | Atezolizumab | Advanced cancers | ORR: 6.4% (n=47) |
| Phase 1b: NCT04280328 | | Daratumumab | Relapsed or refractory MM | Est. completion: 7/2025 |
| Phase 1/1b: NCT03454451 | | CPI-006 (anti-CD73); pembrolizumab | Advanced cancers | Est. completion: 12/2023 |
AstraZeneca | Imaradenant (AZD4635) | Phase 1: NCT02740985 | JCO abstract #5518 | Durvalumab (anti-PD-L1) | mCRPC | ORR 6.1% (n=33) (mono) |
ORR 16.2% (n=37) (combo) |
Phase 1b/2: NCT03381274 | | Oleclumab (anti-CD73) | NSCLC (EGFRm) | Discontinued |
Phase 1: NCT02740985 | | Durvalumab, oleclumab, abiraterone, enzalutamide | Advanced cancers | Est. completion: 12/2021 |
Phase 2: NCT04089553 | | Durvalumab, oleclumab | mCRPC | Est. completion: 6/2022 |
Arcus | Etrumadenant (AB928)* | Phase 1/1b: NCT03720678 (ARC-3) | AACR (2021) Abstract CT129 | SOC (mFOLFOX-6) | mCRC | ORR: 9.1% (n=22) |
Phase 1b/2: NCT04660812 (ARC-9) | JCO Abstract #TPS150 | Zimberelimab (anti-PD1), bevacizumab (anti-VEGF) | mCRC | Est. completion: 12/2023 |
Phase 1: NCT03629756 | | Zimberelimab | Advanced RCC; mCRPCP | Est. completion: 9/2021 |
Phase 2: NCT04262856 (ARC-7) | | Zimberelimab, domvanalimab (anti-TIGIT) | NSCLC | Est. completion: 6/2022 |
Phase 1/1b: NCT03846310 (ARC-4) | | Chemo, pembrolizumab or zimberelimab | EGFRm NSCLC | Est. completion: 2/2023 |
Phase 1b/2: NCT04381832 (ARC-6) | | Zimberelimab, SOC | mCRPC | Est. completion: 10/2023 |
Novartis | NIR178 | Phase 2: NCT03207867 | | PDR001 (anti-PD1) | Advanced cancers | Est. completion: 6/2022 |
Phase 1/2: NCT03207867 | EORTC-NCI-AACR Symp (2018) | Spartalizumab (anti-PD1) | Advanced NSCLC | ORR: 6.5% (n=62) (combo) |
Phase1 1/2: NCT02403193 | JCO abstract #9089 (2018) | Monotherapy | Advanced NSCLC | ORR: 8.3% (n=24) |
Phase 1/1b: NCT04237649 | | KAZ954, PDR001, NZV930 (anti-CD73) | Advanced cancers | Est. completion: 2/2022 |
iTEOS | EOS100850 | Phase 1/1b: NCT03873883 | | Pembrolizumab | Advanced cancers | Est. completion: 12/2022 |
Inupadenant | Phase 1: NCT02740985 | JCO abstract #2562 (2021) | Monotherapy | Advanced cancers | ORR: 4.8% (n=42) |
Cstone Pharma | CS3005 | Phase 1: NCT04233060 | | Monotherapy | Advanced cancers | Est. completion: 12/2021 |
Palobiofarma | PBF-999 | Phase 1: NCT03786484 | | Monotherapy | Advanced cancers | Est. completion: 2/2022 |
Incyte | INCB106385* | Phase 1: NCT04580485 | | INCMGA00012 (anti-PD1) | Advanced cancers | Est. completion: 7/2023 |